Categories
Nevin Manimala Statistics

10-year survival in female breast cancer patients according to ER, PR and HER2 expression: a cancer registry population-based analysis

J Cancer Res Clin Oncol. 2022 Sep 21. doi: 10.1007/s00432-022-04245-1. Online ahead of print.

ABSTRACT

INTRODUCTION: Invasive breast cancer prognosis has significantly improved over time; however, there are few data about the long-term survival.

MATERIALS AND METHODS: We analysed the data on female breast cancer incident during 2004-2005 in the area of the Tuscan Cancer Registry, distinguishing them in five subtypes, according to ER, PgR, HER2, and Ki67 expression: luminal A, luminal B, luminal B/HER2 + , triple-negative, and HER2 + . Effects of subtypes and age on 10 years breast cancer specific survival were analysed by Kaplan-Meier and multivariate Cox analysis.

RESULTS: The majority of breast cancer were luminal B (57%), and 45% of them were diagnosed at pathological stage I. The 10-year survival rates (p < 0.001) were higher among luminal A (90.2%) and lower among HER-2 + patients (70.3%). Prognostic effect of age was statistically significant (p < 0.0004): the 10-year cancer specific survival rates were higher among 40-59 years of age patients (88.5%), lower among 0-39 (75.8%). Luminal A breast cancer patients had a constant low risk throughout 10 years of follow up, while luminal B/HER2 + and triple negative tumours showed a peak 5 years after the diagnosis and then declined.

DISCUSSION: Our study confirmed the prognostic effect of biological subtype also in a long term follow up study; moreover, age at diagnosis showed to influence the outcome, other than stage at diagnosis and treatment. The long term follow up showed a constant risk of death for luminal A and B tumours, whereas for non-luminal cancer a peak 5 years after the diagnosis was found.

PMID:36129548 | DOI:10.1007/s00432-022-04245-1

By Nevin Manimala

Portfolio Website for Nevin Manimala